Market Cap
$1.5B
TYRA
Tyra Biosciences, Inc.
$20.30 ▼ -3.38%
Prev close $21.01Market cap$1.5B
ConsensusStrong Buy
12-mo target$47.45 (+133.8%)
▲ Bullish
Analyst conviction 9/10
43 New Institutional Positions7 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TYRA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$1.4B
Inst. Activity
43 buys / 7 sells
Insider Activity
$200.0M buy / $791.5K sell
Insider Net $
$199.2M
SEC Reports
9
Price chart 30d -19.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 17, 2026 other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Sep 15, 2026 Insider
Rueb Yuliya was granted 2,925 shares
Vice President, Finance (PAO) @ $9.13 ($26.7K)
Sep 15, 2026 Insider
Harris Todd was granted 864 shares
President and CEO @ $9.13 ($7.9K)
Sep 15, 2026 Insider
Sep 14, 2026 SEC Fuhrman Alan was granted 951 shares
Chief Financial Officer @ $9.13 ($8.7K)
Tyra Biosciences filed an automatic shelf registration statement (S-3ASR) on September 14, 2026, registering an unspecif
S-3ASR — Impact 3/10
Tyra Biosciences announced positive initial Phase 2 data for oral dabogratinib in FGFR3-altered low-grade intermediate-r
8-K — Impact 6/10
Tyra Biosciences has amended its existing at-the-market (ATM) equity offering agreement with TD Cowen, increasing the ma
424B5 — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
3,031,972 shares ($96.8M)
Analyst ratings buy % -2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 22 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | Oppenheimer | REITERATE | Outperform | 52% |
| Sep 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 10, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 17, 2026 | Jones Trading | INITIATE | Buy | 51% |
| Jun 10, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| May 19, 2026 | Wolfe Research | INITIATE | Peer Perform | 52% |
| May 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 15, 2026 | Guggenheim | INITIATE | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Aug 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% |
Price targets
Where 11 covering analysts think TYRA trades over the next 12 months.
$47.45 +133.8% upside Strong Buy
Current$20.30 Low$29.00 Median$50.00 High$59.00 11 analysts
$29.00$59.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 5 neutral · avg impact 4.1/10.
NEUTRALS-3ASR3/10
Tyra Biosciences filed an automatic shelf registration statement (S-3ASR) on September 14, 2026, reg
Sep 14, 2026
BULLISH8-K6/10
Tyra Biosciences announced positive initial Phase 2 data for oral dabogratinib in FGFR3-altered low-
Sep 9, 2026
BEARISH424B56/10
Tyra Biosciences has amended its existing at-the-market (ATM) equity offering agreement with TD Cowe
Aug 4, 2026
BEARISH1446/10
Nextech VI Oncology SCSP, a significant VC shareholder, filed a Form 144 to sell 308,379 shares (~$9
Jun 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 17, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Compan
Sep 14, 2026
short_volume
Short Volume: TYRA — 84.3% short (1.0M / 1.1M)
Short: 950,450 | Exempt: 0 | TRF Vol: 1,128,072 | Short Ratio: 84.3% | Off-exchange volume (dark pool + OTC)
Sep 11, 2026
short_volume
Short Volume: TYRA — 86.0% short (0.7M / 0.9M)
Short: 731,082 | Exempt: 0 | TRF Vol: 850,038 | Short Ratio: 86.0% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Compan
Sep 10, 2026
short_volume
Short Volume: TYRA — 77.3% short (1.1M / 1.5M)
Short: 1,142,993 | Exempt: 40,759 | TRF Vol: 1,478,702 | Short Ratio: 77.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.67 | $-0.76–$-0.47 | -33.0% | +2.7% | 2↑ 10↓ | $0.0B | 14 |
| Next Q | $-0.67 | $-0.78–$-0.50 | -17.6% | +5.1% | 3↑ 10↓ | $0.0B | 14 |
| Current FY | $-2.64 | $-2.85–$-2.20 | -31.2% | +1.4% | 2↑ 11↓ | $0.0B | 14 |
| Next FY | $-2.77 | $-3.36–$-2.23 | -5.1% | +6.5% | 2↑ 10↓ | $0.0B | 14 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.665 | — |
| 7d ago | $-0.668 | +0.003 |
| 30d ago | $-0.684 | +0.019 |
| 60d ago | $-0.646 | -0.019 |
| 90d ago | $-0.647 | -0.018 |
Institutional ownership
Which big funds own TYRA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.4B total value (42,642,589 shares) as of 2026-Q2. Top holders: RA, FMR, Jupiter. Net buying activity: 43 institutions added/increased vs 7 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12,198,625 | $389.6M | 28.6% | — |
| FMR LLC | 8,920,513 | $284.9M | 20.9% | — |
| Jupiter Topco LLC | 4,352,448 | $139.2M | 10.2% | — |
| BlackRock, Inc. | 3,031,972 | $96.8M | 7.1% | ADD +36.7% |
| STATE STREET CORP | 2,140,368 | $68.4M | 5.0% | ADD +76.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,508,447 | $48.2M | 3.5% | ADD +34.0% |
| Hood River Capital Management LLC | 1,016,775 | $32.5M | 2.4% | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | 970,734 | $31.0M | 2.3% | ADD +47.4% |
| MARSHALL WACE, LLP | 583,133 | $18.6M | 1.4% | DOUBLED +194.9% |
| GOLDMAN SACHS GROUP INC | 463,477 | $14.8M | 1.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 2,217,929 | 3,031,972 | +36.7% | $96.8M |
| STATE STREET CORP | ADD | 1,216,078 | 2,140,368 | +76.0% | $68.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 1,125,970 | 1,508,447 | +34.0% | $48.2M |
| Hood River Capital Management LLC | NEW | — | 1,016,775 | — | $32.5M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 658,482 | 970,734 | +47.4% | $31.0M |
| MARSHALL WACE, LLP | DOUBLED | 197,748 | 583,133 | +194.9% | $18.6M |
| JENNISON ASSOCIATES LLC | TRIM | 632,432 | 450,964 | -28.7% | $14.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 247,270 | 403,019 | +63.0% | $12.9M |
| BANK OF AMERICA CORP /DE/ | ADD | 209,922 | 349,732 | +66.6% | $11.2M |
| Walleye Capital LLC | DOUBLED | 18,715 | 347,898 | +1758.9% | $11.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 30 transactions. Net $199.2M — $200.0M bought, $791.5K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Rueb Yuliya | Vice President, Finance (PAO) | AWARD | 2,925 | $9.13 | $26.7K |
| Sep 15, 2026 | Harris Todd | President and CEO | AWARD | 864 | $9.13 | $7.9K |
| Sep 15, 2026 | Fuhrman Alan | Chief Financial Officer | AWARD | 951 | $9.13 | $8.7K |
| Sep 15, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 9,078,529 | $22.03 | $200.0M |
| Sep 9, 2026 | Verjee Rehan | Director | BUY | 971.894 | $20.58 | $20.0K |
| May 28, 2026 | Gulfo Adele M. | Director | AWARD | 13,160 | — | — |
| May 28, 2026 | MORE ROBERT J | Director | AWARD | 13,160 | — | — |
| May 28, 2026 | Rothenberg Stephen Michael | Director | AWARD | 13,160 | — | — |
| May 28, 2026 | Moran Susan | Director | AWARD | 13,160 | — | — |
| May 28, 2026 | Verjee Rehan | Director | AWARD | 13,160 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TYRA.
Shares short
9,876,964
Settlement Sep 15, 2026
Change vs prior
+4.6%
Semi-monthly cycle
Days to cover
5.7
At avg daily volume
Of shares outstanding
≈14.4%
Estimate — not % of float
All TYRA filing & press-release reports (9)
- S-3ASR reportSep 14, 2026
- 8-K reportSep 9, 2026
- 424B5 reportAug 4, 2026
- 144 reportJun 26, 2026
- 8-K reportMay 13, 2026
- 3 reportApr 20, 2026
- DEFA14A reportApr 17, 2026
- 8-K reportApr 17, 2026
- 144 reportApr 13, 2026